Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

The Cannigma

APRIL 12, 2023

MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. Like THC , CBN is a natural anti-inflammatory. CBN acts like a weaker version of THC at CB1 receptors, causing very few of THC’s impairing effects, and also less side effects.

Sleep 133

Sleep Data Tincture Research and Development 133

SpeedWeed

FEBRUARY 18, 2021

A new study shows that the inhalation of cannabis could be linked to improvements and better quality of life for those with ulcerative colitis. The study was carried out by researchers in Israel, who looked at how inhaling herbal cannabis impacted ulcerative colitis patients over a period of eight weeks, with continued, steady, use.

Clinical Trials 52

Clinical Trials Treatment Data THC 52

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Veriheal

JANUARY 11, 2023

Gaize is mastering the art of cannabis impairment detection. The Missoula, Montana-based company is gearing up for the launch of its first science-backed real-time cannabis impairment detection device. Studies on cannabis have shown that the plant may cause disorientation, sedation, lack of concentration, and impaired judgment.

Clinical Trials 98

Clinical Trials THC Data Safety 98

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. ” Dr. Gallow prides himself on his work as a South African cannabis advocate and leader in the international medical cannabis research field. It has been fairly slow,” explained Dr. Gallow.

Clinical Trials 113

Clinical Trials Chronic Pain Hydroponic Strains 113

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

MARCH 22, 2020

Mugglehead reports… Previous tests with THC in mice with influenza showed an increase in viral loads. A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Twitter Ads info and privacy.

THC 59

THC Clinical Trials Data Consumption 59

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MAY 10, 2022

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. 11 May 2022.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Project CBD

MARCH 21, 2023

The CBD she took may or may not have helped, but according to a recent survey of tinnitus patients, she wasn’t alone in trying — or at least in being interested in cannabis as a potential remedy. Among the 45 respondents, median age 55, only 10 said they were current cannabis users (19 had never used, and 16 had used in the past).

Cannabinoids 144

Cannabinoids Clinical Trials Sleep Blood Pressure 144

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. The BRC is among the dozens of organizations that have received preliminary approval from the DEA to cultivate cannabis.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Project CBD

MAY 3, 2023

This transcript is adapted from CannMed’s weekly podcast , hosted by Ben Amirault, who recently interviewed Bonni Goldstein, MD, one of the country’s most respected and experienced medical cannabis physicians. Dr. Goldstein has treated thousands of patients with medical cannabis. CBG is not intoxicating or impairing.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Project CBD

AUGUST 6, 2019

Over 200 scientists from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpiblished data. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

NORML

SEPTEMBER 20, 2019

But at the Vegas event, she brought good news: She announced that other universities would host her research, and she recently applied for a third-party cultivation license from the DEA, the only federal agency that can legally provide cannabis for clinical study in the US. Later that night, everyone celebrated at a hotel bar.

DEA 227

DEA Research and Development Clinical Trials Patients 227

The Cannigma

DECEMBER 14, 2021

This synthetic derivative of naturally occurring delta-9-Tetrahydrocannabinol (delta-9-THC) was first reported by noted cannabis chemist Professor Roger Adams at the University of Illinois in 1940. HHC was synthesized in Adams’ laboratory as part of research to understand the active compounds in the cannabis plant.

Research and Development 116

Research and Development Cannabinoids Clinical Trials THC 116

Canna Law Blog

NOVEMBER 6, 2021

But federal lawsuits on cannabis rescheduling provide guidance and suggest that FDA approval is not a requirement for meeting that criterion. Instead, qualifying evidence may come from adequate and well-controlled clinical trials. Phase I trials should be sufficient, and many have been completed using psilocybin.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Veriheal

MAY 3, 2022

Cannabis use disorder (CUD) is often confused with frequent cannabis use , but CUD is significantly more worrisome. The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Fortunately, the U.S. territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. THC is the primary psychoactive compound in cannabis.)

CBD 144

CBD Seed-To-Sale Food Access 144

The Cannigma

OCTOBER 19, 2021

Taken responsibly, both alcohol and cannabis can be a great time. If you’re old enough, you may remember hearing in the anti-drug class at school that when taken together, alcohol and cannabis double the effects of one another. But are the results different for more frequent cannabis users? But what about when you mix the two?

Research and Development 128

Research and Development Clinical Trials Edibles THC 128

Project CBD

AUGUST 6, 2019

Just over 500 participants from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpublished data. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

The Joint Blog

APRIL 17, 2020

According to a new study in the Journal of Clinic Medicine , the use of Tetrahydrocannabinol (THC) could have adverse drug effects when combined with other medications due to drug-drug interactions. Cannabis Sativa, a.k.a Its psychoactive ingredient, THC, has made cannabis a highly used recreational drug for millennia.

Events 48

Events THC Chronic Pain Sleep 48

The Cannigma

JANUARY 13, 2023

Scientists still don’t understand exactly why migraines happen, nor how to cure the condition – but perhaps cannabis can help. Cannabis users have been reporting anecdotal relief for years, but it’s only recently that research has begun to dig into the complexities of migraines and how – or why – cannabis may be able to bring relief.

Terpenes 132

Terpenes Strains THC Treatment 132

Healer

MARCH 26, 2021

Some researchers believe cannabis can help wean prescription opioid users off the addictive and potentially deadly drugs. Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. March 19, 2021.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Green Relief

MAY 13, 2018

The benefits of CBD-rich cannabis concentrates for chronic traumatic encephalopathy (CTE) are well-known among football players and other pro athletes. government still maintains that cannabis is a dangerous drug with no medical value. CBD produces no intoxicating effects, no THC -like high, and its use does not lead to tolerance.

THC 64

THC CBD Cannabinoids Research and Development 64

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In part of one of this series, we analyzed the discussions surrounding using cannabis for mental health. In part two, we took a deep look at using cannabis for depression. In part three, we will analyze the available research concerning cannabis and anxiety. Can you use cannabis for anxiety? Cannabis and Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

The Cannigma

FEBRUARY 11, 2021

Listen & Subscribe: When Mara Gordon started using medical cannabis there wasn’t any lab testing — or any way to know how much of each cannabinoid or terpene was in a given strain. Gordon has been featured in the Netflix documentary, Weed the People , and owns and operates two medical cannabis companies. Why cannabis?

Wellness and Beauty 125

Wellness and Beauty Data Patients Medicine 125

Cannabis Law Report

SEPTEMBER 20, 2021

TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp. Opticann medical cannabis products merge cannabis medicine with modern medicine. CB4 Relief, the THC free CBD softgels formulated with VESIsorb® technology will be available in early November. About Heritage Cannabis Holdings Corp.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

JANUARY 3, 2022

Food and Drug Administration (FDA) during which the company received valuable guidance regarding the clinical development of ANEB-001 in the U.S. Additionally, we are pleased with the guidance provided by the FDA regarding ANEB-001’s clinical and regulatory path in the U.S.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. Condensed Balance Sheet Data. . . Anebulo Pharmaceuticals, Inc. September 30, 2021. . .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

AUGUST 23, 2022

Dr Noor Azmi Ghazali says Cabinet will decide on the need to amend the Dangerous Drugs Act, including creating different definitions for cannabis and hemp, depending on the MOH cannabis and ketum committee’s findings. Syed Saddiq was asking about the latest government plans to approve the use of medical cannabis in Malaysia.

Extraction 52

Extraction Clinical Trials Hemp Epilepsy 52